New crown recombinant subunit protein vaccine: precise identification of the core part of the virus

China News Service, Beijing, April 1st.

When recently accepted China news agency reporter Zhuan Fang, China Ke Xueyuan researcher at the Institute of Microbiology wear even climb pointed out that a major feature of the new crown recombinant subunit protein vaccine is more accurate, "Let antibody can accurately identify the part of the core of the virus.

By the Chinese Kexue Yuan Institute of Microbiology and cooperative enterprises jointly developed novel coronavirus recombinant vaccine (CHO cells), March 10 approved emergency use in China.

Since the 2020 outbreak, in Zhong Keyuan Academy of Sciences under the leadership of the Chinese Center for Disease Control and Prevention Rengao Fu master, including a researcher of the Institute Yan Jinghua, even wearing climbing, including a science and technology research team designed for universal β coronavirus infectious diseases Vaccine construction strategy.

According to Dai Lianpan, recombinant protein vaccines have simple ingredients, high yields, and safe production.

At present, the phase III clinical trial of the new coronavirus recombinant subunit protein vaccine is still in progress, and the relevant data has not been unblinded.

In terms of safety, no serious adverse events related to the vaccine occurred, and most subjects did not experience adverse reactions.

In terms of effectiveness, the results of the two phases of clinical trials have shown that the vaccine produces twice as much neutralizing antibodies as patients who have recovered from new coronary pneumonia.

In the first two phases of clinical trials, the subjects were healthy adults, aged between 18 and 59 years old.

At present, four new crown vaccines in China have been approved for conditional marketing, and the number of vaccinations is gradually increasing.

"Now (vaccine) production capacity is a big problem.

These four new crown vaccines that have been conditionally marketed include two technical routes.

A reporter from China News Agency learned that the new coronavirus recombinant subunit protein vaccine approved for emergency use requires three injections, one month apart between each injection.

Dai Lianpan said that the two injections of the vaccine can produce a level of neutralizing antibodies slightly lower than the serum of recovered patients.

When talking about the battle between the vaccine and the new coronavirus, whether it can overcome the mutation of the virus is a topic of much concern.

Dai Lianpan also told reporters that the researchers used the serum of clinical subjects in the trial phase to neutralize the prototype strain of the new coronavirus and the South African strain (501Y.
V2), and found that the serum has a slight decrease in neutralizing effect on the South African strain.
, But still maintain most of the neutralizing activity.
This also suggests that the vaccine has a certain protective effect on this new variant of the new coronavirus.

He also said that for those unknown and possible virus mutations, whether a more broad-spectrum protective and universal new crown vaccine can be designed is also a topic that the scientific research team is studying.
"There are also some international reports, and some of our own preliminary studies have shown that there is still such a potential possibility.
"